Kornimate/medical-research-clean huggingface dataset:
ultrasound patellar tendon assessment

Conditions: Patellofemoral Pain; Ultrasonography

Summary: 448kilohertz capacitive resistive monopolar radiofrequency is a novel technique in physiotherapy and its usefulness and clinical relevance is still to be investigated at both clinical practice and also in performance. current studies show promising results in different musculoskeletal disorders, however there no studies in the assessment of quality soft tissue in sporty population after the used of this technique.

patellar tendon injuries is is one of the most common musculoskeletal disorders, presenting a high prevalence in sport populations. many factors have been proposed as the cause of pain and dysfunction, however there are no studies analysing possibilities of preventing patellar tendon injuries by using a radiofrequency stimulus. the use of 448kilohertz capacitive resistive monopolar radiofrequency as the focus of the treatment looking for improve the quality of the tissue is still to be explored. the hypothesis of the present project is that focus treatments on 448kilohertz capacitive resistive monopolar radiofrequency on the patellar tendon will produce better outcomes in terms of ultrasound assessment measured by quantified elastography, and this will decreased the possibilities of get injured. the stimulus will be carried out on the patellar tendon region. all interventions will be developed by the same examiner, who is a physiotherapist with 6 years of clinical experience.

Eligibility criteria:
inclusion criteria: * age between 18-65 years. * sporty people with at least 3 days of training per week exclusion criteria: * suffer from knee pain. * sedentary people
stress-induced sleep deficits and a complementary therapy

Conditions: Insomnia Due to Anxiety and Fear

Summary: the covid-19 pandemic and social isolation order induced stress/anxiety as well as cellphone dependence. as a result, sleep disruption and mental distress became major health concerns. gamma-aminobutyric acid type-a receptor (gabaar) is one of the key players in modulating sleep. dihydromyricetin (dhm), an herbal compound, plays a role in gabaar modulation and mitigating anxiety. the investigators' partner in china obtained 288 participants who completed the online survey to gain insight into how stress/anxiety and time spent on cellphones affected sleep and mood. the participants were then enrolled in a randomized placebo-controlled double-blind study to assess the effects of dhm on sleep and improvement on stress/anxiety and cellphone using time.


Eligibility criteria:
inclusion criteria: * healthy subjects were recruited in chengdu and beijing (city) in china, * able and willing to sign informed consent, * between 18 -60 years old at time of consent, * no alcohol, drug, and smoking, * not using sleep medication(s) or other psychiatric medications. exclusion criteria: * pregnant or breastfeeding women, * currently taking any medications for sleep, * reported naps \> 3 times per week * history of sleep apnea, * current alcohol, drug, and smoking
trial of outpatient immunotherapy with rituximab and aldesleukin (il-2) vs. rituximab alone for non-hodgkin's lymphoma

Conditions: Non-Hodgkin's Lymphoma

Summary: the purpose of this research study is to find out if treatment with rituximab in combination with aldesleukin (compared to rituximab alone) decreases the risk of cancer returning, as well as determining what other effects (good and bad) this drug combination has on nhl. rituximab and aldesleukin are not approved in combination by the food and drug administration (fda) for the treatment of non-hodgkins lymphoma; however, rituximab is approved for use by itself to treat nhl.


Eligibility criteria:
inclusion criteria: a patient will be eligible for inclusion in this study if s/he meets all of the following criteria: * has previously undergone beac or beam autologus sct with pbsc rescue for any stage aggressive b-cell nhl, including transformed indolent nhl or mantle cell lymphoma according to real classification - only b-cell lymphomas are permitted. * ecog performance status 0-1. * previously histological documented cd20 +nhl. * is greater than 18 years of age. * is 30-100 days from autologous peripheral blood stem cell transplant. * must meet laboratory values (see protocol for values): absolute neutrophils, hemoglobin and platelets. * has a negative serum pregnancy test within 7 days prior to trial registration (only for female patients of childbearing potential). * if fertile, patient (male or female) has agreed to use physician-approved method of birth control to avoid pregnancy for the duration of the study and for a period of 3 months thereafter. * has signed a patient informed consent form. * has signed a patient authorization form (hipaa). exclusion criteria: patients will be taken off treatment if any of the following occur: * ecog ps \>2. * a history of hypersensitivity to study drugs, or any component thereof, or anaphylactic history to murine protein. * manifested cardiac complications during transplant, including arrthymias, congestive heart failure, angina, or myocardial infarct, or had a decreased lvef to \<45% prior to transplant * on systemic corticosteroids. * diffusion capacity \<60% (corrected) and has decreased 30% or more following transplant * documented disease progression (see section 10.1.6 for definition). * active infection, and/or is known to be seropositive for hepatitis b, hepatitis c, or hiv * pericardial effusion, pleural effusions, or ascites. * a history of very aggressive nhl, such as burkitt's or atypical burkitt's lymphoma * receiving concurrent immunotherapy or rituximab therapy. * previously received a solid organ transplant. * history of cns involvement. * a serious uncontrolled intercurrent medical or psychiatric illness, including serious infection * a history of other malignancy within the last 5 years (except cured basal cell carcinoma of skin and carcinoma in situ of uterine cervix), which could affect the diagnosis or assessment of any of the study drugs. * a pregnant or nursing woman. * unable to comply with requirements of study.
study of the relationship between blood vessels and insulin response in adolescents

Conditions: Diabetes Mellitus, Type 2; Hypertension; Heart Disease; Stroke

Summary: this study is designed to determine whether there is a relationship between the way insulin and blood vessels work. the difference in the interaction between caucasian and african american adolescents will also be examined. this may play a role in the differing rates of heart disease and diabetes between the two groups.

purpose: the purpose of the research is to learn more about how the lining of arteries in the body (called the endothelium) and insulin work in adolescents. abnormalities in how the blood vessels and insulin work in adolescents may cause high blood pressure, type 2 diabetes, stroke and heart disease. healthy adolescents between 8 and 18 years of age are being studied in the ohio state university general clinical research center. two visits will be necessary. one will be a screening visit to determine the child's stage of puberty and obtain a medical history. the second will be the study visit. during the latter, blood vessel function will be determined by studying the change in forearm blood flow before and after blood flow to the forearm is stopped. insulin sensitivity will be determined using glucose water given into a vein.

Eligibility criteria:
inclusion criteria: * caucasian or african american adolescent * between 8 and 18 years of age exclusion criteria: * pregnancy * chronic disease * acute disease * medication requirement

Keywords: insulin sensitivity endothelial function adolescence lipids puberty
a study of smoking cessation patterns in participants undergoing lung surgery

Conditions: Lung Neoplasms; Pulmonary Disease, Chronic Obstructive

Summary: the purpose of this study is to assess the current smoking status and smoking cessation attempts among smokers or recent smoking quitters during the perioperative period, to describe postoperative pulmonary complications (ppcs) and other postoperative complications (pcs) following a lung surgery, and to describe the smoking cessation methods and services patients received from their health care professionals (hcps) and participant's satisfaction among participants with lung cancer, chronic obstructive pulmonary disorder (copd), a pulmonary lesion (example, nodule, or ground glass opacity) or other pulmonary conditions who are admitted to the thoracic surgical unit of the participating hospitals in china.


Eligibility criteria:
inclusion criteria: * participants who have been scheduled for an elective lung surgery by the treating physician's judgement, due to the following conditions: known lung cancer, copd, a pulmonary lesion (example. nodule, ground glass opacity) or other pulmonary conditions * smokers who are or were smoking on average no fewer than 5 cigarettes per day for equal or more than 3 years within 3 months prior to the scheduled surgery, or recent smoking quitters with a history of smoking on average no fewer than 5 cigarettes per day for equal or more than 3 years, who quit smoking between 3 months and 5 years prior to the scheduled surgery * being willing to participate the study and sign the participant informed consent form (icf) exclusion criteria: * participants who have emergency lung surgery due to accident or injury * participants are not likely to be able to complete the 6-month follow-up after the lung surgery
quantifying 18kda tspo expression in the lung in pulmonary artery hypertension (pah)

Conditions: Pulmonary Arterial Hypertension; Healthy

Summary: the aim of this study is to determine whether there is an increase in the tspo pet signal (measured with the radioligand \[11c\]pbr28) in the lungs of patients living with pah relative to age matched controls. if so, tspo pet may be a useful technique to non-invasively monitor response to therapy. to do this, we will perform 2 \[11c\]pbr28 pet scans. the first will quantify the total \[11c\]pbr28 pet signal. this signal is a combination of the specific signal (vs) and the nonspecific signal (vnd). the second scan will be performed following dosing with an unlabelled tspo ligand. by directly measuring the total \[11c\]pbr28 signal (scan 1) and the nonspecific \[11c\]pbr28 signal (scan 2) we can therefore calculate the specific \[11c\]pbr28 signal, and hence the amount of tspo in the lung.


Eligibility criteria:
inclusion criteria: able to provide written informed consent prior to any study mandated procedures. able to lie comfortably on back for up to 90 minutes at a time. fertile females (women of childbearing potential) are eligible to participate after a negative highly sensitive pregnancy test, if they are taking a highly effective method of contraception other than the oral contraceptive pill until the end of relevant systemic exposure. male participants who are fertile are eligible to participate if they are willing to comply with the contraceptive requirements exclusion criteria: unable to provide informed consent and/or are non-fluent speakers of the english language tt genotype at the rs6971 locus clinically-significant renal disease (confirmed by creatinine clearance \<30 ml/min per 1.73m2) clinically-significant liver disease (confirmed by serum transaminases \>2 times than upper normal limit) anaemia confirmed by haemoglobin concentration \<10 g/dl sickle cell disease or thalassaemia history of uncontrolled systemic hypertension acute infection (including eye, dental, and skin infections) chronic inflammatory disease including hiv, and hepatitis b women of childbearing potential who are pregnant or breastfeeding patients who have received an investigational medicinal product (imp) within 5 half-lives of the last dose of the imp or 1 month (which ever is greater) before the baseline visit participation in a research study involving significant ionisation radiation within the last 3 years significant radiation exposure other than dental x-rays in last 1 year positive allen's test. -
a study on the epidemiology and testing of human epidermal growth factor-receptor 2 (her2) in breast cancer in germany

Conditions: Breast Cancer

Summary: this non-interventional study will collect data from routine diagnostics on her2 testing of breast cancer in germany.


Eligibility criteria:
inclusion criteria: * samples derived from men and women of age greater than or equal to (\>/=) 18 years * samples derived from participants with any stage of histologically confirmed invasive breast cancer with her2 diagnostics performed within routine (histo-)pathological workup or * (histo-)pathological work-up of the tumor sample as at or after start of this study * available information on the year of birth of the participant * no pre-selection of tumor samples is allowed. tumor samples have to be documented consecutively in the order of their (histo-)pathological work-up. exclusion criteria: * sample derived from participants with any stage of breast cancer with no her2 diagnostics performed at the time of routine (histo-)pathological work-up. * samples derived prior to the start of this study.
autoreactivity threshold analysis in lupus and immune thrombocytopenia (checkpoints itp and sle)

Conditions: Immune Thrombocytopenia (ITP); Systemic Lupus Erythematosus (SLE)

Summary: the aim of this proposal is to test if anti-baff antibody can restore a normal threshold of tolerance in patients in two auto-immune diseases along the ritux-plus study in immune thrombocytopenia, and along the believe study in sle. this work would help to conclude whether or not the 'double hit' therapy may help to reset the immune system toward a more tolerogenic profile. the aim is to compare the polyreactivity and autoreactivity, of immature (central tolerance) and naïve b cells (peripheral tolerance) in the peripheral blood along the ritux-plus study and the bliss believe study after treatment (b-cell reconstitution time).


Eligibility criteria:
there are no specific inclusion and exclusion criteria for this study. the inclusion and exclusion criteria are those of patients enrolled in the ritux-plus (nct03154385) and bliss believe studies (nct03312907) including the following inclusion criteria: * individuals are affiliated to social security * individuals not be placed under judicial protection, guardianship or curatoship

Keywords: rituximab
assess hdl-c increase and non-hdl lowering effect of torcetrapib/atorvastatin vs. fenofibrate

Conditions: Hyperlipidemia

Summary: the torcetrapib project was terminated on december 2, 2006 due to safety findings. to assess the hdl-c increase and non-hdl lowering effect of torcetrapib/atorvastatin vs. fenofibrate.

for additional information please call: 1-800-718-1021

Eligibility criteria:
inclusion criteria: * diagnosis of fredrickson type iib dyslipidema (mixed hyperlipidemia) * men and women at least 18 years of age exclusion criteria: * women who are pregnant or lactating, or planning to become pregnant. * subjects with a clinically indicated need for statin (hmg-coa reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on ldl-c and hdl-c including fibrates and nicotinic acid * subjects taking any drugs known to be associated with an increased risk of myositis in combination with hmg-coa reductase inhibitors * subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study
mindfulness meditation training in hiv

Conditions: HIV Infections

Summary: the purpose of this study is to investigate whether mindfulness-based stress reduction (mbsr) vs a one-day mbsr seminar improves immune (cd4+ t lymphocytes) and virological (hiv viral load) status in hiv-1 infected adults. the secondary goal of the study is to determine if mbsr vs a one-day mbsr seminar improves self-reported hiv-related quality of life.

mindfulness meditation, which is described as a process of bringing awareness to moment-to-moment experience, has been receiving substantial scientific attention as a process that can be stress and health protective (brown, ryan, \& creswell, 2007). recent reviews by baer (2003), bishop (2002), and grossman et al (2004) support the effectiveness of the standardized and manualized mbsr program in reducing stress and functional disability in a variety of chronic illnesses, although no studies have tested if mbsr impacts clinical markers of hiv, although some evidence suggests that mbsr improves some markers of innate immunity and quality of life in hiv-infected adults (see robinson, mathews, \& witek-janusek, 2003). in this study, we propose to extend this work by investigating the impact of this intervention on biological and functional health status in hiv-positive adults. we propose to determine whether the 8-week mbsr program is more effective than a one-day mbsr seminar in: (1) maintaining immune resistance in hiv infection (i.e. maintaining counts of cd4+ t lymphocytes and reducing hiv viral load), and (2) improving hiv-related quality of life. additional analyses will test for a dose-response effect of mbsr by examining if mbsr class attendance and daily meditation practice are associated with the primary and secondary outcomes. these aims will be tested in a sample of 50 hiv-positive adults that is diverse with respect to ethnicity, gender and sexual orientation.

Eligibility criteria:
inclusion criteria: * diagnosed hiv for \> 6 months * english speaking * 18 years old or older * indicate some distress (\>4 on the patient health questionnaire-9) * willing to be randomized exclusion criteria: * any substance abuse or treatment for a psychiatric disorder in the past 30 days * currently diagnosed with aids or had cd4+ t lymphocytes \<200 cells * hepatitis (a, b, or c) * indicate a regular mind-body practice (e.g., yoga, meditation) in the past six months

Keywords: meditation mindfulness hiv cd4 complementary therapies
effect of cognitive behavioral therapy and phototherapy on glycosylated hemoglobin, clock genes and quality of life in patients with type 2 diabetes mellitus and insomnia

Conditions: Type 2 Diabetes

Summary: purpose: to analyze the efficiency of cognitive behavioral intervention in combination with phototherapy to reduce insomnia and improve glycemic control, quality of life, and clock genes expression in patients with type 2 diabetes mellitus. methods: clinical, quasi-experimental, pre-post, explanatory, non-probability sampling. subjects were invited to participate in hospital juárez de méxico. they received eight sessions of cognitive behavioral therapy in combination with phototherapy. the assessment was carried out with validated instruments for mexican population and gene expression was evaluated by real-time pcr.


Eligibility criteria:
inclusion criteria: have a medical record in the endocrinology service at the hospital juarez de mexico * patients with type 2 diabetes mellitus * age between 40 and 60 years * present insomnia based on the criteria of the diagnostic and diagnostic manual statistics of mental disorders (dsm-v) which defines insomnia such as predominant dissatisfaction with the quantity or quality of sleep, associated with one (or more) of the following symptoms: a) difficulty starting the dream,or b) difficulty maintaining sleep, characterized by awakenings frequent and c) waking up early in the morning with inability to return to sleep; with clinically significant distress or social impairment, work, educational, academic, behavioral or other important areas of operation, at least three nights a week, for a minimum of three months even with favorable sleeping conditions. * sign an informed consent letter and agree to participate in the study. * accept taking a blood sample pre and post intervention * hba1c level above 6.1% (120 mg/dl;7 mmol/l) or bmi less than 34.9 units exclusion criteria: * do not agree to sign the informed consent * have a previous psychiatric diagnosis * have neurological disorders * be diagnosed with type 1 diabetes mellitus or bmi greater than 35 units * missing more than 20% of the sessions (2 sessions)
activity of the auditory cortex during speech perception and speech production in stuttering

Conditions: Stuttering

Summary: the goal of the study is to examine the cortical activity during speech perception and speech production in idiopathic stutterers compared to fluent speakers. therefore, the noninvasive method of magnetoencephalography (meg) is used. a better understanding for the complexity of speech perception and its pathology should be developed. fundamental properties of stuttering are repetitions, prolongations, and blocks. in most cases stuttering emerges between 2 and 5 years of age. the auditory feedback should become less important during development, as soon as information about mispronounced words does not occur anymore. during speech development this control function should be adopted by other systems. in stutterers the dominance of the acoustic control should remain. brain imaging studies with positron emission tomography (pet) or magnetic resonance imaging (mri) show defects in the network of motor system, in the lateralization of speech areas, and functions of the auditory cortex. magnetoencephalographic studies describe a similar variety as cause of stuttering. there may be defects in the auditory feedback, a modification of the lateralization of speech areas, or an alteration of co-action of motor planning and auditory system. the benefit of magnetoencephalography is a very good temporal resolution in the range of milliseconds combined with good spatial resolution. therefore, it is well suited to examine the dynamics of cortical processing during stuttering. in this study evoked components of the auditory systems related to complex sounds, vocals, consonant-vocal combinations, and single words are analyzed. differences of these components in the auditory cortices of stutterers and fluent speakers are hypothesized as well in temporal structure as in localization and lateralization.


Eligibility criteria:
inclusion criteria: * subjects with idiopathic stuttering (for the group of stutterers) * fluently speaking subjects (for the control group) * right handed * normal hearing exclusion criteria: * neurological diseases * psychiatric diseases * medication with neurological effective drugs * implants with magnetic impact

Keywords: magnetoencephalography auditory cortex stuttering non stuttering